ProfileGDS5678 / 1433886_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 88% 85% 89% 88% 89% 91% 88% 89% 88% 88% 88% 88% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.72788
GSM967853U87-EV human glioblastoma xenograft - Control 26.8359188
GSM967854U87-EV human glioblastoma xenograft - Control 36.4279185
GSM967855U87-EV human glioblastoma xenograft - Control 47.1184689
GSM967856U87-EV human glioblastoma xenograft - Control 56.8566988
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.830189
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.13291
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8180388
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.0071489
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8899388
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.8286688
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8711988
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.824588
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.8393588